Logo

Merck KGaA

Amoy Diagnostics CDx Gets Japanese Approval to ID NSCLC Patients Eligible for Tepmetko

The Japanese Ministry of Health, Labor, and Welfare has approved AmoyDx's PLC Panel for use in identifying NSCLC patients with MET exon 14 skipping alterations.

Amoy Diagnostics, Merck KGaA Partner for Lung Cancer Companion Diagnostic Development in China

AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib.

AmoyDx Strikes CDx Development Deal for Merck KGaA Cancer Drug

AmoyDx aims to develop a companion diagnostic for Merck KGaA's non-small cell lung cancer treatment Tepmetko, which was recently approved in Japan.

Metabolon, Merck KGaA Form Metabolomics Alliance

Metabolon's Precision Metabolomics platform identifies pharmacodynamic, efficacy, and response biomarkers and tracks changes in biological pathways.

Japanese Regulators Approve Merck KGaA MET Inhibitor With ArcherDx CDx

The drug, tepotinib, will now be available to treat advanced non-small cell lung cancer patients in Japan with MET exon 14 skipping alterations.

Nov 19, 2019

Personalis, Merck KGaA to Study Cancer Biomarkers Using Immunogenomics Platform

Sep 23, 2019

Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines
Premium

Oct 3, 2018

Merck KGaA, ArcherDx Partner to Develop CDx for Downstream Therapeutic

Sep 10, 2018

Definiens, Merck KGaA Partner for Biomarker Discovery

Jun 20, 2018

Merck KGaA Advancing Tepotinib in MET-Altered Cancer Subpopulations
Premium

Jan 10, 2018

ThermaGenix, MilliporeSigma Ink PCR Reagents Distribution Deal

Dec 27, 2017

HTG Expands Collaboration With Merck KGaA

Nov 27, 2017

Biocartis Gets CE Marking for Two Colorectal Cancer Liquid Biopsy Tests

Sep 26, 2017

FDA Gives Guardant Health IDE Approval for Clinical Trial of Merck KGaA Cancer Drug

Jun 15, 2017

Human Longevity, Merck KGaA Form Cancer Biomarker Partnership

Jun 13, 2017

MilliporeSigma's Proxy-CRISPR Tech Aims to Increase Usability of Native CRISPR Proteins
Premium

May 30, 2017

Lonza's New Investments in Exosome Technologies Reflect Growing Industry Interest
Premium

Apr 11, 2017

MilliporeSigma Developing New Instrument for Single-Molecule Biomarker Detection
Premium

Jan 6, 2017

Guardant Health, Pharma Firms to Develop 500-Gene Liquid Biopsy Panel

Dec 1, 2016

Roche, Merck KGaA Expand PCR Distribution Agreement

Nov 30, 2016

Evotec Inks Deal to Offer Merck KGaA Gene Editing, Silencing Technologies

Oct 12, 2016

HTG, Merck KGaA Ink CDx Development Deal for Lymphoma Drug

Jul 28, 2016

Merck KGaA, AmoyDx Partner on Colorectal Cancer Test for Chinese Market

Apr 15, 2016

Expansion of Liquid Biopsy Test Sites Planned by Merck KGaA, Sysmex
Premium

Apr 7, 2016

Merck KGaA, Sysmex Inostics Garner CE Mark for Liquid Biopsy CRC Test

Breaking News
The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.